Understanding TCEA2: Potential Drug Target and Cellular Processes

Target Name: TCEA2

NCBI ID: G6919

TCEA2

Understanding TCEA2: Potential Drug Target and Cellular Processes

TCEA2 (TCEA2_HUMAN) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the T cell-specific cytoskeleton protein family and is involved in the assembly and maintenance of the cytoskeleton. TCEA2 has been identified as a potential drug target and has been shown to play a role in a variety of biological processes, including cell signaling, inflammation, and fibrosis.

The TCEA2 protein is composed of 191 amino acid residues and has a calculated molecular mass of 21.1 kDa. It is expressed in a variety of tissues, including the brain, heart, kidneys, and liver, and is highly conserved across different species. TCEA2 is associated with several cellular processes, including the cytoskeleton, cell signaling, and inflammation.

One of the well-documented functions of TCEA2 is its role in the assembly and maintenance of the cytoskeleton. The cytoskeleton is a complex protein structure that provides structural support for eukaryotic cells and is involved in a variety of cellular processes, including cell movement, division, and signaling. TCEA2 is a key component of the cytoskeleton and is involved in the assembly and maintenance of the microtubules, which are the basic units of the cytoskeleton.

In addition to its role in the cytoskeleton, TCEA2 is also involved in cell signaling. TCEA2 has been shown to play a role in the regulation of T cell receptor (TCR) signaling, which is a critical process for the development and function of T cells. TCEA2 has been shown to interact with the TCR and contribute to the regulation of TCR signaling by the cytoskeleton.

TCEA2 is also involved in the regulation of inflammation. TCEA2 has been shown to play a role in the regulation of inflammation and immune cell function. TCEA2 has been shown to interact with a variety of immune cells, including T cells, B cells, and macrophages, and has been shown to contribute to the regulation of their function.

Finally, TCEA2 is also involved in the regulation of fibrosis. Fibrosis is a complex process that involves the regulation of cellular growth and the production of extracellular matrix (ECM) components. TCEA2 has been shown to play a role in the regulation of fibrosis and has been shown to contribute to the development of fibrosed tissues.

Despite its involvement in a variety of cellular processes, TCEA2 is not well understood. Currently, there are limited studies that have focused on the regulation of TCEA2. Many of these studies have used cell-based assays, such as immunofluorescence microscopy and biochemical assays, to study the regulation of TCEA2.

In conclusion, TCEA2 is a protein that is involved in a variety of cellular processes, including cell signaling, cytoskeleton assembly and maintenance, inflammation, and fibrosis. Its functions are conserved across different species and it is a potential drug target. Further studies are needed to fully understand the regulation of TCEA2 and its potential as a drug target.

Protein Name: Transcription Elongation Factor A2

Functions: Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. The arresting sites in DNA have the property of trapping a certain fraction of elongating RNA polymerases that pass through, resulting in locked ternary complexes. Cleavage of the nascent transcript by S-II allows the resumption of elongation from the new 3'-terminus

The "TCEA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCEA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets